XOLAIR (also known as Omalizumab)
Xolair is an antibody that binds to human immunoglobulin E (IgE) and prevents the activation of cells that would otherwise mediate allergic reactions.
Adults and adolescents (age >= 12) with moderate to severe asthma with positive skin test for perennial allergens and whose symptoms are not adequately controlled with inhaled corticosteroids.
Xolair should not be used for acute asthma exacerbations.
Xolair is typically administered as a subcutaneous injection by a healthcare administrator. Patient should be monitored afterwards for possible allergic reaction.